Mayne Pharma Group Limited

MYX

AU000000MYX0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 02:10:44 2024-04-26 am EDT			5-day change	1st Jan Change
6.93 ^AUD	-2.39%		+4.05%	+12.68%

Feb. 26	Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	MT
Feb. 25	Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024

An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited from Estetra Srl for AUD 16 million.

June 15, 2023

An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited (ASX:MYX) from Estetra Srl for AUD 16 million on June 16, 2023.

An unknown buyer completed the acquisition of a 4.97% stake in Mayne Pharma Group Limited (ASX:MYX) from Estetra Srl on June 16, 2023.

Latest news about Mayne Pharma Group Limited

Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	Feb. 25	MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024	Feb. 25
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Mayne Pharma Group Limited Approves Election of Anne Lockwood	Nov. 29	CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	Nov. 29
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor	Nov. 03	MT
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	23-10-17
Mayne Pharma Acquires Dermatological Medication	23-09-26	MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC.	23-09-24	CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.	23-09-06	CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting	23-09-04	MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE	23-09-04	MT
Transcript : Mayne Pharma Group Limited, 2023 Earnings Call, Aug 31, 2023	23-08-30
Tranche Update on Mayne Pharma Group Limited's Equity Buyback Plan announced on May 10, 2023.	23-08-30	CI
Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Lupin Gets US FDA Nod for Doxycycline Hyclate Delayed-Release Tablets	23-08-14	MT
Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023	23-07-26	CI
Mithra Pharmaceuticals Cuts Mayne Pharma Group Stake to 4.96%	23-06-19	MT
An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited from Estetra Srl for AUD 16 million.	23-06-15	CI
Transcript : Mayne Pharma Group Limited - Special Call	23-05-09

Chart Mayne Pharma Group Limited

Duration

Period

More charts

Company Profile

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mayne Pharma Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.93 AUD

Average target price

7.035 AUD

Spread / Average Target

+1.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAYNE PHARMA GROUP LIMITED	+12.68%	367M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B

Generic Pharmaceuticals

Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited from Estetra Srl for AUD 16 million.

EPS Revisions